-transparent.png){kind=logo}
We present data on the cellular drug pharmacokinetic alterations correlated with the circumvention of doxorubicin resistance by verapamil in a B16 melanoma cell line. An increased drug uptake, a decreased drug efflux and a different intracellular drug distribution appear to be responsible for the enhancement of doxorubicin cytotoxicity induced by treatment with verapamil in drug-resistant cells. However, doxorubicin pharmacokinetics and cytotoxicity were not affected by verapamil in doxorubicin-sensitive melanoma cells.
Related Publications
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
April 1988,
British journal of cancer,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
June 1990,
Cancer letters,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
January 1995,
European journal of cancer (Oxford, England : 1990),
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
October 2001,
Biological & pharmaceutical bulletin,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
January 1994,
International journal of cancer,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
August 1986,
Cancer research,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
October 1987,
British journal of cancer,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
May 1991,
Cancer letters,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
February 2002,
Investigational new drugs,
M Mariani, and
E Prosperi, and
A Colombo, and
R Supino
January 2009,
Molecular cancer research : MCR,
